TY  -  
T1  - A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus 
SN  -  /  
UR  - http://hdl.handle.net/10138/309256 
T3  -  
A1  - Farmakis, Dimitrios; Agostoni, Piergiuseppe; Baholli, Loant; Bautin, Andrei; Comin-Colet, Josep; Crespo-Leiro, Maria G.; Fedele, Francesco; García-Pinilla, Jose Manuel; Giannakoulas, George; Grigioni, Francesco; Gruchała, Marcin; Gustafsson, Finn; Harjola, Veli-Pekka; Hasin, Tal; Herpain, Antoine; Iliodromitis, Efstathios K.; Karason, Kristjan; Kivikko, Matti; Liaudet, Lucas; Ljubas-Maček, Jana; Marini, Marco; Masip, Josep; Mebazaa, Alexandre; Nikolaou, Maria; Ostadal, Petr; Põder, Pentti; Pollesello, Piero; Polyzogopoulou, Eftihia; Pölzl, Gerhard; Tschope, Carsten; Varpula, Marjut; von Lewinski, Dirk; Vrtovec, Bojan; Yilmaz, Mehmet Birhan; Zima, Endre; Parissis, John 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiester... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - 3121 General medicine, internal medicine and other clinical medicine; Acute heart failure; Advanced heart failure; Inotropes; Inodilators; Levosimendan; Dobutamine; Milrinone; Norepinephrine; LONG-TERM; MORTALITY; INTERMITTENT LEVOSIMENDAN TREATMENT; MILRINONE; CLINICAL CHARACTERISTICS; SYSTOLIC FUNCTION; REPETITIVE USE; CARDIOGENIC-SHOCK; INFUSIONS; QUALITY-OF-LIFE 
N1  -   
PP  -  
ER  -